
PLA–Inhibitor (stoPLA) – New class of NSAIDs for oral and transdermal inflammation treatment

PLA2 enzymes exist as secreted forms and cytosolic forms. The cytosolic or cPLA2 enzymes appear to play a key role in the pathway leading to the formation of platelet activating factor and eicosanoids. PLA2 enzymes cleave phospholipids at the sn-2-position. This metabolic step isinstrumental in a variety of pathogenic processes causingpain and inflammation.
Presently glucocorticoids are used for inhibition of PLA2. Unfortunately, glucocorticoids have serious side effectswhich limit their use as medication for inflammationtreatment.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert